High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule
1997

High-dose mitoxantrone with peripheral blood progenitor cell rescue

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): A Ballestrero, F Ferrando, A Garuti, P Basta, R Gonella, M Esposito, MO Vannozzi, G Sorice, D Friedman, M Puglisi, F Brema, GS Mela, M Sessarego, F Patrone

Primary Institution: Universita di Genova, Genoa, Italy

Hypothesis

Can high-dose mitoxantrone be safely administered with peripheral blood progenitor cell support?

Conclusion

High-dose mitoxantrone can be escalated up to 90 mg/m² with acceptable haematological toxicity when supported by peripheral blood progenitor cells.

Supporting Evidence

  • Haematological recovery was rapid and complete at each NOV dose level without statistically significant differences.
  • PBPCs can be safely reinfused as early as 96 hours after NOV administration.
  • No treatment-related mortality was observed.
  • High response rates were observed in both breast cancer and lymphoma patients.

Takeaway

This study shows that giving a strong cancer drug called mitoxantrone can be done safely in higher doses if doctors also give special cells to help the body recover.

Methodology

Thirty patients with breast cancer or non-Hodgkin's lymphoma received escalating doses of mitoxantrone with melphalan and peripheral blood progenitor cell rescue, with haematological toxicity evaluated daily.

Potential Biases

Potential bias in patient selection and reporting of outcomes.

Limitations

The study did not include a control group for comparison.

Participant Demographics

18 patients had metastatic breast cancer and 12 had non-Hodgkin's lymphoma, with a median age of 44 years.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication